Skip to main content

Remote Job Finders (RJF)

Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft

Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.

Tiziana touts multiple sclerosis win at lower dose as high dose misses mark

In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the higher dose failed to deliver the same benefit.
Scroll to top